RxDoctor Payments Data

Eung Bai, MD

General Practice · Norwalk, CANPI 1962412536

Payments from drug & device makers

$529in general payments, 2019–2025

Across 18 payments — averaging $29.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$296
  • Scilex Pharmaceuticals Inc.$65
  • AbbVie$59
  • Kaleo, Inc.$46
  • Eisai Inc.$22
  • Pfizer$21
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$296
Scilex Pharmaceuticals Inc.1$65
AbbVie2$59
Kaleo, Inc.1$46
Eisai Inc.1$22
Pfizer1$21
GSK1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529 in reported general payments places this provider in the 70th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$47,670
Medicare patients
60
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin18$15,115
JanuviaSitagliptin Phosphate11$11,674
PremarinEstrogens, Conjugated11$2,015
Atorvastatin Calcium178$1,519
Albuterol Sulfate HfaAlbuterol Sulfate30$981
Losartan Potassium88$854
Metformin Hcl120$804
Pioglitazone Hcl30$624
Tamsulosin Hcl43$581
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort13$571
Glipizide53$549
Pantoprazole Sodium37$474
Omeprazole56$454
Ibuprofen66$417
Hydroxychloroquine Sulfate11$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$21$2,01511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 12,963 general practice providers in California.

Other general practice in Norwalk

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →